Our data appear highly clinically relevant because they support the concept that patients with deregulated PTEN/Akt pathway, which comprise 21–42% of prostate cancer patients [45], most likely have overexpression of MTA1 and may benefit from MTA1-targeted therapy. This evidence concerns the gene AKT1 and prostate cancer.